🇺🇸 FDA
Patent

US 12018298

PH20 polypeptide variants, formulations and uses thereof

granted A61KA61K38/00A61K38/28

Quick answer

US patent 12018298 (PH20 polypeptide variants, formulations and uses thereof) held by HALOZYME, INC. expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
HALOZYME, INC.
Grant date
Tue Jun 25 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61K, A61K38/00, A61K38/28, A61K38/47, A61K45/06